P2X Receptor

P2XRs

P2X receptors are a family of seven (P2X1R-P2X7R) cation permeable ligand-gated ion channels (LGICs) that open in response to binding by the extracellular ligand, adenosine 5′-triphosphate (ATP). P2X receptors have a high permeability to Ca^{2+}, Na^{+}, and K^{+} and are expressed widely throughout the nervous, immune, cardiovascular, skeletal, gastrointestinal, respiratory, and endocrine systems.

P2X receptors are widely expressed in excitatory and non-excitatory cells, such as neuron, glia, platelet, epithelia and macrophage, and participate in many important physiological and pathological processes, including synaptic transmission, pain perception, inflammation, cardiovascular modulation, immunomodulation and tumorigenesis.

(E/Z)-Sivopixant

((E/Z)-S-600918) Cat. No.: HY-137451A

(E/Z)-Sivopixant ((E/Z)-S-600918) is a potent **P2X3 receptor** antagonist with an IC_{50} of 4 nM. (E/Z)-Sivopixant can be used for respiratory diseases research.



Purity: 98.64%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

5-BDBD

Cat. No.: HY-101911

5-BDBD, a potent and selective **P2X4** receptor antagonist, inhibits rP2X4R-mediated currents, with an IC_{50} of 0.75 μM. 5-BDBD completely blocks the basal and acute hyperalgesia induced by nitroglycerin (NTG).



Purity: 96.76%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg

8-Bromo-ATP

(8-Bromoadenosine 5'-triphosphate; 8-Br-ATP) Cat. No.: HY-134262

8-Bromo-ATP (8-Bromoadenosine 5'-triphosphate), an ATP analogue, is a purinergic **P2X receptor** agonist. 8-Bromo-ATP shows cytotoxic to multiple myeloma cells with an IC_{50} of 23.1 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg

A 438079

Cat. No.: HY-15488

A 438079 is a potent, and selective **$P2X_7$ receptor** antagonist with pIC_{50} of 6.9.



Purity: 99.74%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

A 438079 hydrochloride

Cat. No.: HY-15488A

A 438079 (hydrochloride) is a potent, and selective **$P2X_7$ receptor** antagonist with pIC_{50} of 6.9.



Purity: 99.79%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

A 839977

Cat. No.: HY-13954

A 839977 is a **P2X7** selective antagonist; it blocks BzATP-evoked calcium influx at recombinant human, rat and mouse P2X7 receptors (IC_{50} values are 20 nM, 42 nM and 150 nM respectively) and reduces inflammatory and neuropathic pain in animal models; the antihyperalgesic effects...



Purity: 98.74%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg

A-317491

Cat. No.: HY-15568

A-317491 is a potent, selective and non-nucleotide antagonist of **$P2X_3$** and **$P2X_{2/3}$ receptors**, with K_is of 22, 22, 9, and 92 nM for **$hP2X_3$**, **$rP2X_3$**, **$hP2X_{2/3}$**, and **$rP2X_{2/3}$**, respectively.



Purity: 99.28%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

A-317491 sodium salt hydrate

Cat. No.: HY-15568A

A-317491 sodium salt hydrate is a potent, selective and non-nucleotide antagonist of **$P2X_3$** and **$P2X_{2/3}$ receptors**, with K_is of 22, 22, 9, and 92 nM for **$hP2X_3$**, **$rP2X_3$**, **$hP2X_{2/3}$**, and **$rP2X_{2/3}$**, respectively.



Purity: 99.65%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

A-740003

Cat. No.: HY-50697

A-740003 is a potent, selective and competitive **P2X7 receptor** antagonist with IC_{50} values are 18 and 40 nM for rat and human P2X7 receptors, respectively.



Purity: 98.31%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

A-804598

Cat. No.: HY-100483

A-804598 is a CNS penetrant, competitive and selective **P2X7** receptor antagonist with IC_{50}s of 9 nM, 10 nM and 11 nM for mouse, rat and human **P2X7** receptors, respectively.



Purity: 98.77%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

AF-353

(Ro-4)

Cat. No.: HY-14483

AF-353 (Ro-4) is a potent, selective and orally bioavailable **P2X3/P2X2/3 receptor** antagonist, with a **pIC_{50}** of 8.0 for both human and rat P2X3, and with a **pIC_{50}** of 7.3 for human P2X2/3.



Purity: 98.95%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

Aurintricarboxylic acid

Cat. No.: HY-122575

Aurintricarboxylic acid is a nanomolar-potency, allosteric antagonist with selectivity towards αβ-methylene-ATP-sensitive **P2X1Rs** and **P2X3Rs**, with **IC_{50}**s of 8.6 nM and 72.9 nM for rP2X1R and rP2X3R, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg

AZ10606120 dihydrochloride

Cat. No.: HY-108669

AZ10606120 dihydrochloride is a selective, high affinity antagonist for **P2X7 receptor (P2X7R)** at human and rat with an **IC_{50}** of ~10nM. AZ10606120 dihydrochloride is little or no effect at other P2XR subtypes.



Purity: 99.04%
Clinical Data:
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg

AZD9056 hydrochloride

Cat. No.: HY-19427A

AZD9056 hydrochloride is a selective orally active inhibitor of **P2X7** which plays a significant role in inflammation and pain-causing diseases.



Purity: 98.82%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

BAY-1797

Cat. No.: HY-130605

BAY-1797 is a potent, orally active, and selective **P2X4** antagonist, with an **IC_{50}** of 211 nM against human P2X4. BAY-1797 displays no or very weak activity on the other P2X ion channels. BAY-1797 shows anti-nociceptive and anti-inflammatory effects.



Purity: 98.66%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Bullatine A

Cat. No.: HY-N5025

Bullatine A, a diterpenoid alkaloid of the genus Aconitum, possesses anti-rheumatic, anti-inflammatory and anti-nociceptive effects.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

BX430

Cat. No.: HY-110237

BX430 is a potent and selective noncompetitive allosteric **human P2X4 receptor channels** antagonist with an **IC_{50}** of 0.54 μM. BX430 has species specificity. BX430 is used for chronic pain and cardiovascular disease.



Purity: 99.87%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

BzATP triethylammonium salt

Cat. No.: HY-136254

BzATP triethylammonium salt acts as a **P2X receptor** agonist with **pEC_{50}**s of 8.74, 5.26, 7.10, 7.50, 6.19, 6.31, 5.33 for P2X1, P2X2, P2X3, P2X2/3, P2X4 and P2X7, respectively.



Purity: ≥95.0%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

CE-224535

(PF-04905428)

Cat. No.: HY-15487

CE-224535 is a selective **$P2X_7$ receptor** antagonist.



Purity: 98.88%
Clinical Data: Phase 2
Size: 5 mg, 10 mg, 25 mg, 50 mg

Eliapixant

(BAY 1817080)

Cat. No.: HY-109170

Eliapixant (BAY 1817080) is a potent and selective antagonist of **P2X3 receptor**, with an **IC_{50}** of 8 nM. Eliapixant can be used for the research of refractory chronic cough.



Purity: 99.69%
Clinical Data: Phase 2
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Filapixant

Cat. No.: HY-109173

Filapixant is a **purinoreceptor** antagonist extracted from patent WO2016091776A1, example 348. Filapixant is the active reference substance of Eliapixant.



Purity: 98.78%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Gefapixant

(MK-7264; AF-219)

Cat. No.: HY-101588

Gefapixant (MK-7264) is an orally active P2X3 receptor (**P2X3R**) antagonist with IC_{50}s of ~30 nM versus recombinant hP2X3 homotrimers and 100-250 nM at hP2X2/3 heterotrimeric receptors.



Purity: 99.32%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

GSK-1482160

Cat. No.: HY-19888

GSK-1482160 is an orally available negative allosteric modulator of the **P2X7** receptor. P2X7 receptors are involved in the production of pro-inflammatory cytokines, such as Il-1β, by central and peripheral immune cells.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

GW791343 dihydrochloride

Cat. No.: HY-15469

GW791343 dihydrochloride is a P2X7 allosteric modulator; exhibits species-specific activity and acts as a negative allosteric modulator of human P2X7 (pIC50 = 6.9 - 7.2).



Purity: 98.03%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

GW791343 trihydrochloride

Cat. No.: HY-15470

GW791343 3Hcl is a P2X7 allosteric modulator; exhibits species-specific activity and acts as a negative allosteric modulator of human P2X7 (pIC50 = 6.9 - 7.2).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Indophagolin

Cat. No.: HY-134807

Indophagolin is a potent, indoline-containing **autophagy** inhibitor (IC_{50}=140 nM). Indophagolin antagonizes the purinergic receptor **$P2X_4$** as well as $P2X_1$ and $P2X_3$ with IC_{50}s of 2.71, 2.40 and 3.49 μM, respectively.



Purity: 98.05%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

JNJ-42253432

Cat. No.: HY-123481

JNJ-42253432 is a CNS-penetrant, high-affinity and orally active **P2X7** antagonist, with pK_i values of 9.1 and 7.9 for rat and human P2X7 channels, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

JNJ-47965567

Cat. No.: HY-101418

JNJ-47965567 is a centrally permeable, high-affinity, selective **P2X7** antagonist, with **pK_i**s of 7.9 and 8.7 for human and rat P2X7, respectively. JNJ-47965567 can be used to probe the role of central P2X7 in rodent models of CNS pathophysiology.



Purity: 99.77%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

JNJ-54166060

Cat. No.: HY-124300

JNJ-54166060 is a potent and selective **P2X7 receptor** antagonist, with **IC_{50}**s of 4/115/72 nM for human/rat/mouse P2X7 receptor, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

JNJ-54175446

Cat. No.: HY-117508

JNJ-54175446 is a potent and selective brain penetrant **P2X7 receptor** antagonist, with **pIC_{50}**s of 8.46 and 8.81 for hP2X7 receptor and rP2X7 receptor, respectively.



Purity: 99.49%
Clinical Data: Phase 2
Size: 1 mg, 5 mg, 10 mg

JNJ-55308942

Cat. No.: HY-123857

JNJ-55308942 is a high-affinity, selective, brain-penetrant **P2X7** functional antagonist (hP2X7: IC_{50}=10 nM, K_i=7.1 nM; rP2X7: IC_{50}=15 nM, K_i=2.9 nM). JNJ-55308942 is orally bioavailable, binds to brain P2X7 and blocks IL-1β release from adult rodent brain.



Purity: 99.95%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

KN-62

Cat. No.: HY-13290

KN-62 is a selective and reversible inhibitor of calmodulin-dependent protein kinase II (**CaMK-II**) with a K_i of 0.9 μM for rat brain CaMK-II. KN-62 directly binds to the calmodulin binding site of CaMK-II.



Purity: 99.45%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Lappaconitine

((+)-Lappaconitine)

Cat. No.: HY-N0383

Lappaconitine, isolated from Aconitum sinomontanum Nakai, was characterized as analgesic principle. IC50 value: Target: In vitro: In vivo: Lappaconitine was characterized as analgesic principle by our laboratory.



Purity: 98.04%
Clinical Data: Launched
Size: 10 mg, 25 mg, 100 mg

Lu AF27139

Cat. No.: HY-132981

Lu AF27139 is a potent, selective, and orally active antagonist of **P2X7 receptor** (IC_{50}s of 12 and 2.4 nM for human and rat, K_is of 22, 54, and 13 nM for mouse, human, and rat, respectively). Lu AF27139 has rodent-active and CNS-penetrant character.



Purity: 99.69%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Minodronic acid

(YM-529)

Cat. No.: HY-16322

Minodronic acid (YM-529) is a third-generation bisphosphonate that directly and indirectly prevents proliferation, induces **apoptosis**, and inhibits metastasis of various types of cancer cells. Minodronic acid (YM-529) is an antagonist of purinergic **P2X2/3** receptors involved in pain.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Minodronic acid-d4

(YM-529-d4)

Cat. No.: HY-16322S

Minodronic acid-d4 is deuterium labeled Minodronic acid. Minodronic acid (YM-529) is a third-generation bisphosphonate that directly and indirectly prevents proliferation, induces apoptosis, and inhibits metastasis of various types of cancer cells.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

MRS4738

Cat. No.: HY-143890

MRS4738 is a potent and high affinity **P2Y14R** antagonist. MRS4738 exhibits anti-hyperallodynic and antiasthmatic activity in vivo.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

NF023 hexasodium

Cat. No.: HY-108676

NF023 hexasodium is a selective and competitive **$P2X_1$ receptor** antagonist, with IC_{50} values of 0.21 μM, 28.9 μM, > 50 μM and > 100 μM for human $P2X_1$, $P2X_3$, $P2X_2$, and $P2X_4$-mediated responses respectively.



Purity: ≥99.0%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

NF110

Cat. No.: HY-108671

NF110 is a **$P2X_3$** receptor antagonist (K_i = 36 nM) and inactive toward P2Y receptors stably expressed (IC_{50}s > 10 M). NF110 blocks alphabeta-methylene-ATP-induced currents (IC_{50} = 527 nM) in rat dorsal root ganglia neurons.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

NF279

Cat. No.: HY-D0976

NF279 is a potent selective and reversible **P2X1 receptor** antagonist, with an IC_{50} of 19 nM. NF279 displays good selectivity over P2X2, P2X3 (IC_{50}=1.62 μM), P2X4 (IC_{50}>300 μM).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

NF449 octasodium

Cat. No.: HY-112461A

NF449 octasodium is a highly potent **$P2X_1$ receptor** antagonist, with **IC_{50}**s of 0.28, 0.69, and 120 nM for $rP2X_1$, $rP2X_{1+5}$, $P2X_{2+3}$, respectively. NF449 octasodium is a $G_{s\alpha}$ -selective **G Protein** antagonist.



Purity: ≥95.0%
Clinical Data: No Development Reported
Size: 1 mg

Opiranserin

(VVZ-149)

Cat. No.: HY-109067

Opiranserin (VVZ-149), a non-opioid and non-NSAID analgesic candidate, is a dual antagonist of **glycine transporter type 2 (GlyT2)** and **serotonin receptor 2A (5HT2A)**, with **IC_{50}**s of 0.86 and 1.3 μM, respectively. Opiranserin shows antagonistic activity on rP2X3 (IC_{50}=0.87 μM).



Purity: >98%
Clinical Data: Phase 3
Size: 1 mg, 5 mg

Opiranserin hydrochloride

(VVZ-149 hydrochloride)

Cat. No.: HY-109067A

Opiranserin (VVZ-149) hydrochloride, a non-opioid and non-NSAID analgesic candidate, is a dual antagonist of **glycine transporter type 2 (GlyT2)** and **serotonin receptor 2A (5HT2A)**, with **IC_{50}**s of 0.86 and 1.3 μM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Oxatomide

Cat. No.: HY-123205

Oxatomide is a potent and orally active dual **H1-histamine receptor** and **P2X7 receptor** antagonist with antihistamine and anti-allergic activity. Oxatomide almost completely blocks the ATP-induced current in **human P2X7 receptors** (**IC_{50}** of 0.95 μM).



Purity: 99.47%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

P2X receptor-1

Cat. No.: HY-139627

P2X receptor-1 is a potential inhibitor of **P2X receptor** for the treatment of pain and inflammation.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

P2X3 antagonist 34

Cat. No.: HY-135976

P2X3 antagonist 34 is a potent, selective and orally active **P2X3 homotrimeric receptor** antagonist with **IC_{50}**s of 25 nM, 92 nM and 126 nM for **human P2X3**, **rat P2X3** and **guinea pig P2X3 receptors**, respectively.



Purity: 99.42%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

P2X3 antagonist 36

Cat. No.: HY-143568

P2X3 antagonist 36 is a **P2X3** antagonist extracted from patent WO2019081343A1 compound 156.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

P2X3 antagonist 37

Cat. No.: HY-143576

P2X3 antagonist 37 is a potent **P2X3 receptor** antagonist with an **IC_{50}** of 32.45 nM for hP2X3 (WO2021115225A1, example 68).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

P2X7 receptor antagonist-1

Cat. No.: HY-145466

P2X7 receptor antagonist-1 is a purinergic **P2X7 receptor** antagonist. P2X7 receptor antagonist-1 has efficacy of combating neuroinflammation.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Piromelatine

(Neu-P11)

Cat. No.: HY-105285

Piromelatine (Neu-P11) is a **melatonin MT_1/MT_2** receptor agonist, **serotonin $5\text{-}HT_{1A}$/$5\text{-}HT_{1D}$** agonist, and **serotonin $5\text{-}HT_{2B}$** antagonist.



Purity: 99.21%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

PPADS tetrasodium

Cat. No.: HY-101044

PPADS tetrasodiuma is a non-selective **P2X receptor** antagonist. PPADS tetrasodiuma blocks recombinant P2X1, -2, -3, -5 with IC_{50}s ranging from 1 to 2.6 μM. PPADS tetrasodiuma blocks native P2Y2-like (IC_{50}~0.9 mM) and recombinant P2Y4 (IC_{50}~15 mM) receptors.



Purity: ≥95.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg

PSB-12062

(N-(p-Methylphenylsulfonyl)phenoxazine)

Cat. No.: HY-101910

PSB-12062 is a potent and selective **P2X4** antagonist with an IC_{50} of 1.38 μM for human P2X4.



Purity: 99.06%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Ro 0437626

Cat. No.: HY-108673

Ro 0437626 is a selective purinergic **($P2X_1$)** receptor antagonist (IC_{50} = 3 μM), but shows low affinity for P2X2, P2X3 and P2X2/3 receptors (IC_{50} > 100 μM).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

RO-3

Cat. No.: HY-19978

RO-3 is a potent, CNS-penetrant, and orally active **$P2X_3$** and **$P2X_{2/3}$** antagonist with pIC_{50}s of 5.9 and 7.0 for human homomultimeric $P2X_3$ and heteromultimeric $P2X_{2/3}$ receptors, respectively.



Purity: 97.32%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg

Ro-51

Cat. No.: HY-14485

Ro-51 is a potent and selective dual $P2X_3$/$P2X_{2/3}$ antagonist, with IC_{50} of 2 nM and 5 nM for $P2X_3$ and $P2X_{2/3}$, respectively. Ro-51 can be used for the research for pain.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Sivopixant

(S-600918)

Cat. No.: HY-137451

Sivopixant (S-600918) is a potent and selective **P2X3 receptor** antagonist (P2X3 IC_{50}=4.2 nM; P2X2/3 IC_{50}=1100 nM). Sivopixant shows strong analgesic effect.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

TC-P 262

Cat. No.: HY-108668

TC-P 262 is a potent **P2X3** inhibitor. TC-P 262 shows inhibition by bindings to hP2X3. TC-P 262 has the potential for the research of rheumatoid arthritis, cough, and pain.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Zeaxanthin dipalmitate

(Physalien)

Cat. No.: HY-N9182

Zeaxanthin dipalmitate (Physalien) is a wolfberry-derived carotenoid, has anti-inflammatory and anti-oxidative stress effects.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

α,β-Methylene ATP trisodium

Cat. No.: HY-108652

α,β-Methylene ATP trisodium, a phosphonic analog of ATP, is a P2X3 and P2X7 receptor ligand. α,β-Methylene ATP trisodium is a highly selective agonist for P2X1 and P2X3, with practically no activity at P2X2,4-7.



Purity: ≥95.0%
Clinical Data: No Development Reported
Size: 5 mg

α,β-Methylene-ATP dilithium

Cat. No.: HY-134440

α,β-Methylene ATP dilithium, a phosphonic analog of ATP, is a P2X3 and P2X7 receptor ligand. α,β-Methylene ATP dilithium is a highly selective agonist for **P2X1** and **P2X3**, with practically no activity at P2X2,4-7.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg